Off-label use of rhBMP-2 as bone regeneration strategies in mandibular ameloblastoma unicystic

• Autor(a) principal: Silva,Henrique Celestino Lima e
• Data de Publicação: 2017
• Outros Autores: Cheim Junior,Adonai Peixoto, Moreno,Roberto, Miranda,Sérgio Luis de
• Tipo de documento: Relatório
• Idioma: eng
• Título da fonte: Einstein (São Paulo)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082017000100092
• topic: Bone morphogenetic proteins; Ameloblastoma; Mandibular neoplasms; Bone regeneration; Bone transplantation; Case reports

ABSTRACT Jawbone reconstruction after tumor resection is one of the most challenging clinical tasks for maxillofacial surgeons. Osteogenic, osteoinductive, osteoconductive and non-antigenic properties of autogenous bone place this bone as the gold standard for solving problems of bone availability. However, the need for a second surgical site to harvest the bone graft increases significantly both the cost and the morbidity associated with the reconstructive procedures. Bone grafting gained an important tool with the discovery of bone morphogenetic proteins in 1960. Benefit of obtaining functional and real bone matrix without need of second surgical site seems to be the great advantage of use bone morphogenetic proteins. This study analyzed the use of rhBMP-2 in unicystic ameloblastoma of the mandible, detailing its structure, mechanisms of cell signaling and biological efficacy, in addition to present possible advantages and disadvantages of clinical use of rhBMP-2 as bone regeneration strategy.